Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY

被引：0
|
作者：
Slamon, Dennis J. [1 ]
Buyse, Marc [2 ]
Press, Michael F. [3 ]
机构：
[1] UCLA David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Int Inst Drug Dev, Louvain, Belgium
[3] Univ So Calif, Los Angeles, CA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：663 / 665
页数：3
相关论文
共 50 条
  • [1] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [2] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [3] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [4] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [5] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [6] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [7] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Angelica Fasolo
    Elena De Benedictis
    Luca Gianni
    [J]. Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
  • [8] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Hudis, CA
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
  • [9] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [10] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    [J]. WOMENS HEALTH, 2009, 5 (02) : 135 - 147
12345